For Rare Difficult Cancer New Drug Is a \'Major Advance\'

For Rare, Difficult Cancer, New Drug Is a 'Major Advance'

13:01 EDT 24 Apr 2019 | Medscape

Tagraxofusp, the first-ever drug for blastic plasmacytoid dendritic-cell neoplasm, is being called a major advance. Data are now published in the New England Journal of Medicine.
Medscape Medical News

Original Article: For Rare, Difficult Cancer, New Drug Is a 'Major Advance'

For Rare Difficult Cancer New Drug Is a \'Major Advance\'

For Rare, Difficult Cancer, New Drug Is a 'Major Advance'

More From BioPortfolio on "For Rare, Difficult Cancer, New Drug Is a 'Major Advance'"